Dr. Donald Lyle Budenz, MD

Dr. Budenz practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Budenz's NPI, 1063455749, was assigned on June 13, 2006. Dr. Budenz graduated from Harvard Medical School in 1987. Dr. Budenz holds North Carolina license 2011-01358.

Dr. Budenz's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Budenz's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. Dr. Budenz is also affiliated with UNC Health Chatham. The medical group on file is University of Miami Health System. Dmand AI also links Dr. Budenz to 1 more hospital, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Budenz practices, 4 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Budenz's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Budenz is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Budenz's licenses on file in 3 states: North Carolina, Florida and Pennsylvania.

Dmand AI lists cataract, cataract surgery with lens implant, dry eye, glaucoma, glaucoma surgery and inflammation of iris among the conditions Dr. Budenz treats.

CMS data shows 488 Medicare services from Dr. Budenz across 9 procedure codes in 2024, for 172 Medicare patients. Medicare paid $46,272 for them.

CMS counts 172 Medicare patients who saw Dr. Budenz in 2024. The largest group is 65 to 74, with 79 patients. 73% of them have high blood pressure, and 69% have high cholesterol. 9% are also on Medicaid. Their average risk score is 1.15, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Budenz's median patient age at 75, with 57% women.

In 2024, Dr. Budenz wrote 1,474 Medicare Part D claims for 339 patients. 60% of them were for generic drugs. CMS names the drug for 1,404 of them, across 11 drugs with 11 or more claims each, at $48,151 in total drug cost. In 2023, CMS named 1,516 claims across 12 drugs.

Dr. Budenz accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 40 procedures of cataract surgery by Dr. Budenz, more than 59% of the clinicians it reports for that procedure.

Dmand AI links 193 papers to Dr. Budenz, published from 2006 to 2024. 2017 was the busiest year, with 8. The most frequent topics are Glaucoma, Intraocular Pressure and Glaucoma, Open-Angle. Dr. Budenz has published most often in Ophthalmology. Dr. Budenz's most frequent co-authors are Steven J. Gedde, MD, Kuldev Singh, MD and Janey L. Wiggs, MD.

Dmand AI links Dr. Budenz to 5 clinical trials. Conditions studied include Glaucoma and Ocular Hypertension. Tema Christian Eye Center sponsors the most, 2.

CMS Open Payments shows 60 general payments to Dr. Budenz from 12 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 47% of the total. Alcon Laboratories Inc paid the most, $12,142.

Dmand AI lists 23 awards for Dr. Budenz, most recently President in 2024.

Dr. Budenz graduated from Harvard Medical School in 1987. Dr. Budenz is a member of AAO.

Dr. Budenz is in network with 18 carriers, including Elevance, Aetna and United Healthcare. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.